See more : HeidelbergCement AG (HDELY) Income Statement Analysis – Financial Results
Complete financial analysis of SIGA Technologies, Inc. (SIGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SIGA Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Granite Falls Energy, LLC (GFGY) Income Statement Analysis – Financial Results
- MEC Resources Limited (MMR.AX) Income Statement Analysis – Financial Results
- Affinity Beverage Group, Inc. (ABVG) Income Statement Analysis – Financial Results
- Selected Investments Bonds (SIIBO.CO) Income Statement Analysis – Financial Results
- Unilever PLC (ULVR.L) Income Statement Analysis – Financial Results
SIGA Technologies, Inc. (SIGA)
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.92M | 110.78M | 133.67M | 124.96M | 26.74M | 477.05M | 12.27M | 14.99M | 8.18M | 3.14M | 5.52M | 8.97M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 483.12K | 500.00K | 500.00K | 700.00K | 100.00K |
| Cost of Revenue | 17.83M | 32.96M | 26.54M | 25.74M | 15.09M | 108.29M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -945.40K | -400.00K | -200.00K | 0.00 | 0.00 |
| Gross Profit | 122.09M | 77.82M | 107.13M | 99.22M | 11.66M | 368.77M | -4.41M | -4.72M | -4.95M | -7.69M | -8.34M | -9.24M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 1.43M | 900.00K | 700.00K | 700.00K | 100.00K |
| Gross Profit Ratio | 87.26% | 70.25% | 80.14% | 79.40% | 43.59% | 77.30% | -35.95% | -31.51% | -60.60% | -244.93% | -151.06% | -103.02% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 295.69% | 180.00% | 140.00% | 100.00% | 100.00% |
| Research & Development | 16.43M | 24.11M | 9.94M | 10.94M | 13.30M | 13.02M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 18.37M | 22.66M | 17.42M | 11.61M | 9.94M | 9.15M | 8.30M | 4.17M | 2.94M | 1.77M | 1.73M | 2.61M | 1.70M | 2.90M | 900.00K | 700.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.88M | 12.30M | 13.71M | 24.99M | 200.99M | 1.42M | 1.88M | 25.74M | 1.15M | 734.17K | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.41M | -188.47M | 11.82M | 9.53M | 0.00 | 8.13M | 7.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.04M | 35.12M | 17.32M | 14.00M | 13.25M | 12.88M | 12.30M | 13.71M | 10.58M | 12.52M | 13.24M | 11.41M | 25.74M | 9.28M | 8.27M | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 800.00K |
| Other Expenses | 0.00 | -24.11M | 710.15K | 719.14K | 726.11K | 78.94M | 16.79K | -1.66M | 42.20K | 1.07K | 1.50K | 522.00 | 0.00 | 0.00 | 4.35B | 0.00 | 0.00 | 0.00 | 0.00 | 2.12M | 136.75K | 0.00 | 117.26K | 945.40K | 400.00K | 200.00K | 100.00K | 0.00 |
| Operating Expenses | 22.04M | 35.12M | 18.03M | 14.72M | 13.98M | 13.67M | 13.21M | 14.62M | 11.59M | 13.51M | 14.67M | 13.29M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 8.51M | 4.40M | 5.90M | 3.00M | 1.50M |
| Cost & Expenses | 56.30M | 68.08M | 44.58M | 40.46M | 29.06M | 121.95M | 29.89M | 34.33M | 24.72M | 24.34M | 28.52M | 31.51M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 7.57M | 4.00M | 5.70M | 3.00M | 1.50M |
| Interest Income | 4.16M | 0.00 | 101.17K | 2.48M | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.26K | 34.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.02M | 15.77M | 15.48M | 14.76M | 14.06M | 266.73K | 455.81K | 1.21M | 172.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.68K | 550.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 538.29K | 517.64K | 522.37K | 529.81K | 527.00K | 69.63K | 132.19K | 174.28K | 247.36K | 351.56K | 463.14K | 419.36K | 568.29K | 625.34K | 475.09K | 459.88K | 1.25M | 1.56M | 1.33M | 1.05M | 739.56K | 317.03K | 556.86K | 945.40K | 400.00K | 200.00K | 100.00K | 900.00K |
| EBITDA | 84.16M | 43.22M | 89.62M | 85.03M | 1.03M | 355.17M | -23.44M | -25.45M | -38.48M | -211.13M | -23.13M | -21.78M | -21.87M | -27.57M | -11.40M | -8.28M | -6.21M | -5.25M | -1.20M | -8.32M | -4.56M | -3.05M | -2.70M | -6.14M | -3.08M | -5.00M | -1.80M | -500.00K |
| EBITDA Ratio | 60.15% | 39.48% | 67.12% | 68.47% | 3.84% | 91.00% | -142.43% | -139.01% | -198.83% | -664.03% | -408.36% | -246.53% | -312.41% | 17.57% | -41.01% | -104.33% | -120.00% | -29.85% | -17.10% | -283.50% | -603.84% | -884.91% | -199.45% | -1,238.31% | -620.00% | -740.00% | -314.29% | -500.00% |
| Operating Income | 83.62M | 42.70M | 89.09M | 84.50M | 500.09K | 355.10M | -18.85M | -31.01M | -30.95M | -209.67M | -23.52M | -22.54M | -31.38M | -12.72M | -11.88M | -8.74M | -7.46M | -6.81M | -2.53M | -9.45M | -5.29M | -3.37M | -3.26M | -7.08M | -3.50M | -5.20M | -2.30M | -1.40M |
| Operating Income Ratio | 59.76% | 38.55% | 66.65% | 67.62% | 1.87% | 74.44% | -153.63% | -206.94% | -378.59% | -6,677.64% | -426.07% | -251.21% | -246.60% | -66.21% | -86.01% | -108.32% | -111.41% | -93.84% | -29.87% | -513.72% | -723.60% | -976.95% | -281.31% | -1,466.21% | -700.00% | -1,040.00% | -328.57% | -1,400.00% |
| Total Other Income/Expenses | 4.16M | 1.43M | 218.94K | -10.99M | -7.86M | 56.54M | -19.48M | -8.67M | -8.04M | -2.27M | -1.28M | 632.05K | 8.94M | -37.45M | -5.74M | 137.53K | 1.82M | -3.09M | 244.79K | 74.97K | -136.75K | 0.00 | -392.37K | -155.59K | 0.00 | -1.30M | 0.00 | -900.00K |
| Income Before Tax | 87.78M | 44.13M | 89.31M | 73.51M | -10.18M | 411.64M | -38.33M | -39.68M | -38.99M | -211.93M | -24.80M | -22.37M | -22.44M | -19.40M | -17.62B | -8.60M | -5.64M | -9.90M | -2.29M | -12.06M | -5.43M | 0.00 | -3.65M | -7.24M | 0.00 | -6.50M | 0.00 | -2.30M |
| Income Before Tax Ratio | 62.73% | 39.84% | 66.81% | 58.83% | -38.06% | 86.29% | -312.41% | -264.78% | -476.88% | -6,749.87% | -449.26% | -249.39% | -176.31% | -100.96% | -127,556.62% | -106.62% | -84.17% | -136.39% | -26.99% | -655.72% | -742.29% | 0.00% | -315.15% | -1,498.41% | 0.00% | -1,300.00% | 0.00% | -2,300.00% |
| Income Tax Expense | 19.71M | 10.23M | 19.86M | 17.17M | -2.94M | -10.17M | -2.09M | 13.88K | 461.98K | 53.53M | -7.62M | -7.84M | -36.03M | 15.47M | 5.74M | -137.53K | -1.82M | 3.09M | -244.79K | 493.36K | -18.26K | -34.06K | 467.79K | 706.06K | 100.00K | 1.40M | -100.00K | 0.00 |
| Net Income | 68.07M | 33.90M | 69.45M | 56.34M | -7.24M | 421.81M | -36.24M | -39.70M | -39.45M | -265.46M | -17.18M | -14.53M | 13.59M | -28.20M | -17.62M | -8.60M | -5.64M | -9.90M | -2.29M | -9.37M | -5.28M | -3.33M | -3.73M | -7.79M | -3.60M | -6.60M | -2.20M | -2.30M |
| Net Income Ratio | 48.65% | 30.61% | 51.96% | 45.09% | -27.08% | 88.42% | -295.34% | -264.87% | -482.53% | -8,454.68% | -311.22% | -161.95% | 106.82% | -146.73% | -127.56% | -106.62% | -84.17% | -136.39% | -26.99% | -509.65% | -721.11% | -967.06% | -321.66% | -1,612.35% | -720.00% | -1,320.00% | -314.29% | -2,300.00% |
| EPS | 0.95 | 0.46 | 0.92 | 0.71 | -0.09 | 5.28 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.57 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| EPS Diluted | 0.95 | 0.46 | 0.91 | 0.71 | -0.09 | 5.10 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.09 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| Weighted Avg Shares Out | 71.36M | 72.93M | 75.32M | 79.26M | 81.03M | 79.92M | 78.77M | 57.19M | 53.78M | 53.41M | 52.05M | 51.64M | 50.93M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.58M | 6.54M | 3.89M | 3.07M |
| Weighted Avg Shares Out (Dil) | 71.68M | 73.55M | 76.40M | 79.44M | 82.18M | 82.71M | 78.87M | 57.19M | 53.78M | 53.42M | 52.37M | 51.64M | 54.06M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.59M | 6.55M | 3.89M | 3.07M |
SIGA Technologies, Inc. Being Investigated on Behalf of SIGA Technologies, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating SIGA Technologies, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA...
SIGA Technologies, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by SIGA Technologies, Inc. (SIGA)
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the...
Siga Technologies Inc. (SIGA) Flat As Market Gains: What You Should Know
In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $8.43, denoting no change from the preceding trading day.
Siga Technologies Inc. (SIGA) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Siga Technologies Inc. (SIGA) closed at $7.88, marking a -1.38% move from the previous day.
Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $7.51, indicating a -0.53% shift from the previous trading day.
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of...
Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study
So-called “bull traps” often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc SIGA — and there may be another one today.
SIGA Technologies: Poised For A Potential Windfall From Monkeypox Emergency Declaration
SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients failed to meet its primary endpoint but showed safety. SIGA's reliance on US...
Source: https://incomestatements.info
Category: Stock Reports